Abstract
Between February 2003 and May 2003, we conducted a clinical trial to evaluate the clinical efficacy of Gatifloxacin (GFLX) in acute sinusitis in adults. Subjects were 98 acute sinusitis patients, in 82 of whom clinical efficacy was evaluated. Based on the clinical conclusion, we administered GFLX for 7 days, with the following results:
1. Clinical efficacy was 78.6% in mild cases, 92.5% in moderate, and 78.6% in severe, with excellent good efficacy observed in 85.4%. Overall efficacy was assessed as excellent in 58 cases, good in 12, fair in 7, and poor in 5 cases.
2. Efficacy based on X ray findings was assessed as excellent in 35 cases, good in 20, fair in 13, and poor in 14, with efficacy rated as 82.9%(68/82).
3. MIC90 of GFLX for main bacteria associated with acute sinusitis was 4μg/mL for Staphylococcus aurens, 0.5μg/mL for Streptococcus pneumoniae, 0.03μg/mL for Haemophilus influenzae, 0.5μg/mL for Streptococcus pyogenes, and 0.12μg/mL for Moraxella catarrhalis.
4. No side effects were observed.
We therefore conclude that GFLX is useful in treating acute sinusitis in the presence of bacterial resistance.
